NCT00423306已完成2 期
A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 15
- 试验地点
- 6
- 主要终点
- Response Rate
研究概览
简要总结
The study of safety of a new organic arsenic compound in the treatment of advanced hepatocellular carcinoma
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •HCC diagnosed by histology or clinical evidence supported by liver mass(es) at least 2cm in the longest diameter and AFP equal to or more than 500 ng/mL in cirrhosis or chronic HBV or HCV infection
- •Male or female patients ≥ 18 years of age
- •Patients who have a life expectancy of at least 12 weeks
- •Patients who have at least one uni-dimensional measurable lesion by CT-scan or MRI according to Response Evaluation Criteria in Solid Tumors (RECIST).
- •Patients who have an Eastern Co-operative Oncology Group (ECOG) performance status of 0 - 2 (see Appendix 4).
- •Patients who have received local therapy, such as surgery, radiation therapy, hepatic arterial embolization, chemo-embolization, radio-frequency ablation or cryo-ablation are eligible, provided that they either have a target lesion which has not been subjected to local therapy and/or the target lesion(s) within the field of the local therapy has shown an increase of ≥ 25% in the size. Furthermore, the local therapy applied to target or non-target lesions needs to have been completed at least 8 weeks prior to study inclusion. Lesions treated with external beam radiation therapy are not acceptable as target lesions, unless they fulfil the conditions described above.
- •No more than one prior chemotherapy based regimen is allowed. Patients can receive up to two regimes where target therapies have been used (washout)
- •Cirrhotic status of Child-Pugh Class A or B only (Appendix 5).
- •Adequate hepatic function at screening as assessed by the following:
- •Platelet count ≥ 60 x 109/L
- •Hemoglobin ≥ 8.5 g/dl
- •Total bilirubin ≤ 3 mg/dl
- •ALT and AST ≤ 5 x upper limit of normal
- •Serum creatinine ≤ 2.0 x the upper limit of normal
- •PT-INR ≤ 2.3 or PT ≤ 6 seconds above control
- •Patients who give written informed consent prior to any study specific screening procedures with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.
排除标准
- •Previous malignancy (except for cervical carcinoma in situ, adequately treated basal cell carcinoma, or superficial bladder tumors [Ta, Tis and T1] or other malignancies curatively treated > 2 years prior to entry)
- •Congestive heart failure > NYHA Class II
- •Cardiac arrhythmias requiring anti-arrythmics (excluding beta blockers or digoxin for chronic stable atrial fibrillation) or QTc greater than 450 msec.
- •Active coronary artery disease or cardiac ischemia
- •Active clinically serious bacterial, viral or fungal infections (> grade 2 NCI-CTCAE, Version 3)
- •Known history of human immunodeficiency virus (HIV) infection for less than 2 years or uncontrolled disease on antiretroviral medication
- •Metastatic brain or meningeal tumors
- •Patients with seizure disorder requiring medication (such as anti-epileptics)
- •History of confusion or dementia or neurological condition that could mask a potential adverse response to the study drug (or something along these lines)
- •History of organ allograft
- •Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
- •Known or suspected allergy to the investigational agent or any agent given in association with this trial
- •Any condition that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study
- •Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 14 days prior to the start of study drug. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial
研究组 & 干预措施
Single Arm
Experimental
干预措施: Darinaparsin (Drug)
结局指标
主要结局
Response Rate
时间窗: 6 months
次要结局
- Survival (overall and progression free)(6 months)
- toxicities(6 months)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
2 期
Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow CancersHematologic NeoplasmsBone Marrow NeoplasmsNon-Hodgkin's LymphomaNCT00421213Alaunos Therapeutics50
已完成
1 期
Study of ZIO-101 in Multiple MyelomaMultiple MyelomaNCT00303199Alaunos Therapeutics35
已完成
2 期
A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001bMultiple MyelomaNCT00423644Alaunos Therapeutics17
已完成
2 期
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)Hepatocellular CarcinomaNCT01752933Astex Pharmaceuticals, Inc.52
已完成
1 期
Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC)Advanced Hepatocellular CarcinomaNCT00731445Zeria Pharmaceutical43